Despite the increasing evidence for BBB alterations in PD—the second most common neurodegenerative disorder with rapidly rising prevalence—with the a-synuclein accumulation possibly resulting in altered tight junction and transporter protein levels [17], the need for BBB-permeable molecules might remain an additional complication for the delivery of PET imaging agents, particularly in early disease stages [11]. Here, SNCA is linked to Parkinson disease.